0001209191-22-007915.txt : 20220208
0001209191-22-007915.hdr.sgml : 20220208
20220208210945
ACCESSION NUMBER: 0001209191-22-007915
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220204
FILED AS OF DATE: 20220208
DATE AS OF CHANGE: 20220208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doyle Ramona
CENTRAL INDEX KEY: 0001856069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 22603562
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-04
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856069
Doyle Ramona
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
Chief Medical Officer
Class A Common Stock
2022-02-04
4
A
0
38499
0.00
A
95834
D
Class A Common Stock
2022-02-04
4
A
0
2392
0.00
A
98226
D
Class A Common Stock
2022-02-04
4
F
0
981
11.40
D
97245
D
Stock Option (Right to Buy)
11.40
2022-02-04
4
A
0
76998
0.00
A
2032-02-04
Class A Common Stock
76998
76998
D
Stock Option (Right to Buy)
11.40
2022-02-04
4
A
0
4784
0.00
A
2022-02-04
2032-02-04
Class A Common Stock
4784
4784
D
Stock Option (Right to Buy)
2.48
2030-12-30
Class A Common Stock
694053
694053
D
This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter.
This RSU vested immediately upon the grant date.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
/s/ Nathan Hatfield, attorney-in-fact
2022-02-08